Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England

Colin D Jones, Richard H Greenwood, Aseema Misra, Max O Bachmann, Colin D Jones, Richard H Greenwood, Aseema Misra, Max O Bachmann

Abstract

Objective: To estimate the incidence of diabetic retinopathy in relation to retinopathy grade at first examination and other prognostic characteristics.

Research design and methods: This was a dynamic cohort study of 20,686 people with type 2 diabetes who had annual retinal photography up to 14 times between 1990 and 2006. Cumulative and annual incidence rates were estimated using life tables, and risk factors for progression were identified using Cox regression analysis.

Results: Of 20,686 patients without proliferative diabetic retinopathy (PDR) or sight-threatening maculopathy at their first retinal examination (baseline), 16,444 (79%) did not have retinopathy, 3,632 (18%) had nonproliferative retinopathy, and 610 (2.9%) had preproliferative retinopathy. After 5 years, few patients without retinopathy at baseline developed preproliferative retinopathy (cumulative incidence 4.0%), sight-threatening maculopathy (0.59%), or PDR (0.68%); after 10 years, the respective cumulative incidences were 16.4, 1.2, and 1.5%. Among those with nonproliferative (background) retinopathy at baseline, after 5 years [corrected] 23% developed preproliferative retinopathy, 5.2% developed maculopathy, and 6.1% developed PDR; after 10 years, the respective cumulative incidences were 53%, 9.6%, and 11%. Patients with nonproliferative retinopathy at baseline were five times more likely to develop preproliferative, PDR, or maculopathy than those without retinopathy at baseline (adjusted hazard ratio 5.0 [95% CI 4.4-5.6]).

Conclusions: Few patients without diabetic retinopathy at the initial screening examination developed preproliferative retinopathy, PDR, or sight-threatening maculopathy after 5-10 years of follow-up. Screening intervals longer than a year may be appropriate for such patients.

Figures

Figure 1
Figure 1
Annual incidence, with 95% CIs, of preproliferative retinopathy, PDR, or maculopathy in patients with nonproliferative retinopathy or without retinopathy at baseline. Follow-up truncated after 12 years because of small numbers (

References

    1. Scanlon PH. The English national screening programme for sight-threatening diabetic retinopathy. J Med Screen 2008;15:1–4
    1. American Diabetes Association Diabetic retinopathy. Diabetes Care 1998;21:157–159
    1. Royal College of Ophthalmologists Guidelines for Diabetic Retinopathy. London, Royal College of Ophthalmologists, 1997, p. 1–104
    1. Bachmann MO, Nelson SJ. Impact of diabetic retinopathy screening on a British district population: case detection and blindness prevention in an evidence-based model. J Epidemiol Community Health 1998;52:45–52
    1. Misra A, Bachmann MO, Greenwood RH, et al. Trends in yield and effects of screening intervals during 17 years of a large UK community-based diabetic retinopathy screening programme. Diabet Med 2009;26:1040–1047
    1. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989;107:244–249
    1. Retinopathy Working Party A protocol for screening for diabetic retinopathy in Europe. Diabet Med 1991;8:263–267
    1. Harding S, Greenwood R, Aldington S, et al. ; Diabetic Retinopathy Grading and Disease Management Working Party Grading and disease management in national screening for diabetic retinopathy in England and Wales. Diabet Med 2003;20:965–971
    1. Early Treatment Diabetic Retinopathy Study Research Group Grading diabetic retinopathy from stereoscopic colour fundus photographs—an extension of the modified Airlie House classification. ETRS report number 10. Ophthalmol 1991;98:786–806
    1. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527–532
    1. Younis N, Broadbent DM, Vora JP, Harding SP; Liverpool Diabetic Eye Study Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003;361:195–200
    1. Kohner EM, Stratton IM, Aldington SJ, et al. Relationship between the severity of retinopathy and progression to photocoagulation in patients with type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med 2001;18:156–163
    1. Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156–163
    1. Manaviat MR, Rashidi M, Afkhami-Ardekani M. Four years incidence of diabetic retinopathy and effective factors on its progression in type II diabetes. Eur J Ophthalmol 2008;18:572–577

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj